Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Open access

Published version of a preprint

Abstract

Purpose: Onvansertib is a highly specific inhibitor of polo-like kinase 1 (PLK1), with demonstrated safety in solid tumors. We evaluated, preclinically and clinically, the potential of onvansertib in combination with chemotherapy as a therapeutic option for KRAS-mutant colorectal cancer. Patients and Methods: Preclinical activity of onvansertib was assessed (i) in vitro in KRAS wild-type and -mutant isogenic colorectal cancer cells and (ii) in vivo, in combination with irinotecan, in a KRAS-mutant xenograft model. Clinically, a phase Ib trial was conducted to investigate onvansertib at doses 12, 15, and 18 mg/m2 (days 1–5 and 14–19 of a 28-day cycle) in combination with FOLFIRI/bevacizumab (days 1 and 15) in patients with KRAS-mutant metastatic colorectal cancer who had prior oxaliplatin exposure. Safety, efficacy, and changes in circulating tumor DNA (ctDNA) were assessed. Results: In preclinical models, onvansertib displayed superior activity in KRAS-mutant than wild-type isogenic colorectal cancer cells and demonstrated potent antitumor activity in combination with irinotecan in vivo. Eighteen patients enrolled in the phase Ib study. Onvansertib recommended phase II dose was established at 15 mg/m2. Grade 3 and 4 adverse events (AE) represented 15% of all treatment-related AEs, with neutropenia being the most common. Partial responses were observed in 44% of patients, with a median duration of response of 9.5 months. Early ctDNA dynamics were predictive of treatment efficacy. Conclusions: Onvansertib combined with FOLIFRI/bevacizumab exhibited manageable safety and promising efficacy in second-line treatment of patients with KRAS-mutant metastatic colorectal cancer. Further exploration of this combination therapy is ongoing. See related commentary by Stebbing and Bullock, p. 2005

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-23-3053

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Effect of onvansertib monotherapy and in combination with irinotecan in colorectal cancer preclinical models. A, Isogenic KRAS MUT and KRAS WT DLD1 cells were treated at the indicated concentrations of onvansertib for 72 hours. Bar graph (mean ± SEM, n = 3) represents relative viability to DMSO for each cell line. B, KRAS MUT and KRAS WT DLD1 cells were treated for 24 hours with DMSO or 100 nmol/L onvansertib. Bar graph (mean ±SEM, n = 3) represents the percentage of mitotic cells measured by flow cytometry (positive staining for phospho-H3 Ser28). Data analyzed by two-way ANOVA using Šídák multiple comparisons test. C and D, BALB/c nude mice inoculated with HCT116 cells were treated with vehicle, onvansertib, irinotecan, or the combination for 42 days. C, Mean tumor volumes ± SEM, n = 7–8/group. Tumor volumes were compared at day 42 using a one-way ANOVA with Tukey multiple comparison tests. D, Mean ± SEM body weight changes from baseline. *** and **** indicate P ≤ 0.001 and 0.0001, respectively.
Figure 1. Effect of onvansertib monotherapy and in combination with irinotecan in colorectal cancer preclinical models. A, Isogenic KRAS MUT and KRAS WT DLD1 cells were treated at the indicated concentrations of onvansertib for 72 hours. Bar graph (mean ± SEM, n = 3) represents relative viability to DMSO for each cell line. B, KRAS MUT and KRAS WT DLD1 cells were treated for 24 hours with DMSO or 100 nmol/L onvansertib. Bar graph (mean ±SEM, n = 3) represents the percentage of mitotic cells measured by flow cytometry (positive staining for phospho-H3 Ser28). Data analyzed by two-way ANOVA using Šídák multiple comparisons test. C and D, BALB/c nude mice inoculated with HCT116 cells were treated with vehicle, onvansertib, irinotecan, or the combination for 42 days. C, Mean tumor volumes ± SEM, n = 7–8/group. Tumor volumes were compared at day 42 using a one-way ANOVA with Tukey multiple comparison tests. D, Mean ± SEM body weight changes from baseline. *** and **** indicate P ≤ 0.001 and 0.0001, respectively.CC BY-NC-ND · PubMed Central
Figure 2. Clinical efficacy of onvansertib in combination with FOLFIRI/bevacizumab. A, Swimmer plot according to dose level. Each line represents a patient. B, Waterfall plot of maximum percent change in target lesions from baseline. C,KRAS mutation at baseline according to best response. D, Kaplan–Meier curve of PFS. The gray shadow indicates 95% CI. The data are from n = 16 patients evaluable for efficacy. PR = partial response, SD = stable disease, PD = progressive disease.
Figure 2. Clinical efficacy of onvansertib in combination with FOLFIRI/bevacizumab. A, Swimmer plot according to dose level. Each line represents a patient. B, Waterfall plot of maximum percent change in target lesions from baseline. C,KRAS mutation at baseline according to best response. D, Kaplan–Meier curve of PFS. The gray shadow indicates 95% CI. The data are from n = 16 patients evaluable for efficacy. PR = partial response, SD = stable disease, PD = progressive disease.CC BY-NC-ND · PubMed Central
Figure 3. Early changes in KRAS MAF are associated with clinical benefit. A, Percentage change in KRAS MAF after one cycle of treatment from baseline according to best response. Fifteen patients were included in the analyses, 7 with PR, and 8 with either SD or PD as best response. Data analyzed by unpaired t test with Welch correction, **, P < 0.01. B, ROC curve for clinical response prediction, showing the sensitivity and specificity of KRAS-mutant ctDNA decrease after one cycle to predict clinical response. 95% CIs are shown in blue. C, Patient with ≥90% decrease in KRAS MAF from baseline were considered molecular responders. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the KRAS-mutant ctDNA plasma test to predict clinical response are reported.
Figure 3. Early changes in KRAS MAF are associated with clinical benefit. A, Percentage change in KRAS MAF after one cycle of treatment from baseline according to best response. Fifteen patients were included in the analyses, 7 with PR, and 8 with either SD or PD as best response. Data analyzed by unpaired t test with Welch correction, **, P < 0.01. B, ROC curve for clinical response prediction, showing the sensitivity and specificity of KRAS-mutant ctDNA decrease after one cycle to predict clinical response. 95% CIs are shown in blue. C, Patient with ≥90% decrease in KRAS MAF from baseline were considered molecular responders. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the KRAS-mutant ctDNA plasma test to predict clinical response are reported.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 53

Metadata

Authors
Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J.
Affiliations
  • Mayo Clinic (US)
  • City Of Hope National Medical Center (US)
  • 3Cardiff Oncology Inc., San Diego, California.
  • USC Norris Comprehensive Cancer Center (US)
Corresponding author
Lenz, Heinz-Josef
Venue
Clinical Cancer Research
Published
2024-01-16
Volume
30
Issue
10
Pages
2039-2047
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4390942811
Cited by
49
References
36
Citations by year
2026: 13 · 2025: 24 · 2024: 12
FWCI
8.39
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
n/a (n/a)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
onvansertib, polo-like kinase 1 inhibitor, KRAS-mutant colorectal cancer, metastatic colorectal cancer, second-line therapy, FOLFIRI, bevacizumab, irinotecan, circulating tumor DNA, predictive biomarkers, combination chemotherapy, dose escalation, neutropenia
MeSH terms
Bevacizumab, Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Protein Serine-Threonine Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-23-3053
The paper
Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024). Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-3053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.